Brind.
  1. An executive order was issued to accelerate research related to drug policy in the US.
  2. Executive order shifts cannabis classification from Schedule I to Schedule III.
  3. US cannabis rescheduling is expected to favor Tilray.

Tilray benefits from the easing of federal research restrictions on cannabis.

1 report, 1 independent Updated Jul 19
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Tilray benefits from the easing of federal research restrictions on cannabis.

Who's involved

What this event is mainly about
Tilray

Keep exploring

Part of

US cannabis rescheduling is expected to favor Tilray. All 1 developments

Within An executive order was issued to accelerate research related to drug policy in the US.

The entities involved

Coverage

Newest first; wire copies grouped
  • StockStoryTilray (TLRY) Stock Trades Up, Here Is Why Shares of cannabis company Tilray Brands (NASDAQ:TLRY) jumped 3.3% in the afternoon session after President Trump signed a bill that could ease federal rese